NEWPORT BEACH, Calif.— Vivera is pleased to announce the launch of LabPort, a comprehensive software solution designed to streamline and integrate the diagnostic testing and results
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals, Inc. is pleased to welcome Aaron Kheriaty, M.D., to its Board of Advisors as the Medical Ethics Advisor of
NEWPORT BEACH, Calif. — Vivera Pharmaceuticals announced today that through its co-owned diagnostics laboratory, Pala Diagnostics, no-cost COVID-19 testing will be offered to all Southern California
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals announced today that Sahar S. Pugh will join the Company as General Counsel and Vice President of Legal Affairs.
NEWPORT BEACH, Calif.- Vivera Pharmaceuticals is pleased to announce the Company’s Co-Founder and Vice President of Sales, Olivia Karpinski, was named the Honoree in the Company
Vivera Pharmaceuticals Announces New BioSciences Division Focused on Research and Development in Drug Delivery
NEWPORT BEACH, Calif. – Vivera Pharmaceuticals today announced the introduction of Vivera BioSciences, a new division of the Company focused exclusively on research and innovation
Forward-looking and cautionary statements:
Statements made on our website may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Vivera, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Vivera and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Vivera’s future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Vivera’s expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Vivera, reference should be made to Vivera’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Vivera’s CSE Listing Statement. The forward-looking information contained on our website is made as of the date of the release of such statement and Vivera does not intend, and expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents on our site.